Ocular sarcoidosis

Seminars in Respiratory and Critical Care Medicine

Volumn 31, Issue 4, 2010, Pages 452-462

  Baughman, Robert P ^a   Lower, Elyse E ^a,b   Kaufman, Adam H ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b Oncology Hematology Care   (United States)

Author keywords

eye; ocular; Sarcoidosis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; LOTEPREDNOL ETABONATE; METHOTREXATE; MYCOPHENOLIC ACID; PREDNISOLONE ACETATE; TRIAMCINOLONE; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

BLINDNESS; CATARACT; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG MECHANISM; DRUG WITHDRAWAL; EUROPE; EYE DISEASE; EYE EXAMINATION; EYE SARCOIDOSIS; GENETIC LINKAGE; GLAUCOMA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INTRAOCULAR PRESSURE; JAPANESE; OPTIC NERVE DISEASE; ORBIT DISEASE; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; SARCOIDOSIS; SCLERITIS; SIDE EFFECT; UNITED STATES; UVEITIS; VISUAL IMPAIRMENT; ANTAGONISTS AND INHIBITORS; COMPLICATION; EPIDEMIOLOGY; EYE DISEASES; JAPAN; PATHOPHYSIOLOGY;

ANTIBODIES, MONOCLONAL; EYE DISEASES; HUMANS; JAPAN; METHOTREXATE; SARCOIDOSIS; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS;

EID: 77955041186     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0030-1262213     Document Type: Review

References (90)

1. Ohara K, Judson M A., Baughman R P. Clinical Aspects of Ocular Sarcoidosis In: Drent M, Costabel U Sarcoidosis. Wakefield, UK Charlesworth Group 2005 188-209
2. Ohara K, Okubo A, Sasaki H, Kamata K. Intraocular manifestations of systemic sarcoidosis. Jpn J Ophthalmol 1992 36 452-457
3. Dana M R., Merayo-Lloves J, Schaumberg D A. et al. Prognosticators for visual outcome in sarcoid uveitis. Ophthalmology 1996 103 1846-1853
4. Jakob E, Reuland M S., Mackensen F et al. Uveitis subtypes in a German interdisciplinary uveitis centeranalysis of 1916 patients. J Rheumatol 2009 36 127-136
5. Judson M A., Baughman R P., Teirstein A S., Terrin M L., Yeager H Jr. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. Sarcoidosis Vasc Diffuse Lung Dis 1999 16 75-86
6. Takahashi T, Azuma A, Abe S, Kawanami O, Ohara K, Kudoh S. Significance of lymphocytosis in bronchoalveolar lavage in suspected ocular sarcoidosis. Eur Respir J 2001 18 515-521
7. Hunninghake G W., Costabel U, Ando M et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999 16 149-173
8. Herbort C P., Rao N A., Mochizuki M, members of Scientific Committee of First International Workshop on Ocular Sarcoidosis. International criteria for the diagnosis of ocular sarcoidosis: results of the first International Workshop On Ocular Sarcoidosis (IWOS). Ocul Immunol Inflamm 2009 17 160-169
9. Kawaguchi T, Hanada A, Horie S, Sugamoto Y, Sugita S, Mochizuki M. Evaluation of characteristic ocular signs and systemic investigations in ocular sarcoidosis patients. Jpn J Ophthalmol 2007 51 121-126
10. Evans M, Sharma O, LaBree L, Smith R E., Rao N A. Differences in clinical findings between Caucasians and African Americans with biopsy-proven sarcoidosis. Ophthalmology 2007 114 325-333
11. Pietinalho A, Ohmichi M, Lfroos A B., Hiraga Y, Selroos O. The prognosis of pulmonary sarcoidosis in Finland and Hokkaido, Japan: a comparative five-year study of biopsy-proven cases. Sarcoidosis Vasc Diffuse Lung Dis 2000 17 158-166
12. Pietinalho A, Ohmichi M, Hiraga Y et al. The mode of presentation of sarcoidosis in Finland and Hokkaido, Japan: a comparative analysis of 571 Finnish and 686 Japanese patients. Sarcoidosis 1996 13 159-166
13. Baughman R P., Teirstein A S., Judson M A. et al, Case Control Etiologic Study of Sarcoidosis (ACCESS) research group. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001 164 (10 Pt 1) 1885-1889
14. Rothova A, Alberts C, Glasius E, Kijlstra A, Buitenhuis H J., Breebaart A C. Risk factors for ocular sarcoidosis. Doc Ophthalmol 1989 72 287-296
15. Prabhakaran V C., Saeed P, Esmaeli B et al. Orbital and adnexal sarcoidosis. Arch Ophthalmol 2007 125 1657-1662
16. Pattishall E N., Strope G L., Spinola S M., Denny F W. Childhood sarcoidosis. J Pediatr 1986 108 169-177
17. Shetty A K., Gedalia A. Childhood sarcoidosis: a rare but fascinating disorder. Pediatr Rheumatol Online J 2008 6 16
18. Rybicki B A., Maliarik M J., Bock C H. et al. The Blau syndrome gene is not a major risk factor for sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999 16 203-208
19. Rossman M D., Thompson B, Frederick M et al, ACCESS Group. HLA-DRB11101: a significant risk factor for sarcoidosis in blacks and whites. Am J Hum Genet 2003 73 720-735
20. Rybicki B A., Sinha R, Iyengar S, Gray-McGuire C, Elston R C., Iannuzzi M C., SAGA Study Consortium. Genetic linkage analysis of sarcoidosis phenotypes: the sarcoidosis genetic analysis (SAGA) study. Genes Immun 2007 8 379-386
21. Spagnolo P, Sato H, Marshall S E. et al. Association between heat shock protein 70/Hom genetic polymorphisms and uveitis in patients with sarcoidosis. Invest Ophthalmol Vis Sci 2007 48 3019-3025
22. Bradley D A., Baughman R P., Raymond L, Kaufman A H. Ocular manifestations of sarcoidosis. Semin Respir Crit Care Med 2002 23 543-548
23. Jabs D A., Johns C J. Ocular involvement in chronic sarcoidosis. Am J Ophthalmol 1986 102 297-301
24. Silver M R., Messner L V. Sarcoidosis and its ocular manifestations. J Am Optom Assoc 1994 65 321-327
25. Boyd S R., Young S, Lightman S. Immunopathology of the noninfectious posterior and intermediate uveitides. Surv Ophthalmol 2001 46 209-233
26. Obenauf C D., Shaw H E., Sydnor C F., Klintworth G K. Sarcoidosis and its ophthalmic manifestations. Am J Ophthalmol 1978 86 648-655
27. Rothova A. Ocular involvement in sarcoidosis. Br J Ophthalmol 2000 84 110-116
28. Raymond L A., Spaulding A G., Vilter R W. Peripheral retinal neovascularization in sarcoidosis with thalassemia. Ann Ophthalmol 1978 10 745-748
29. Steahly L P. Sarcoidosis and peripheral neovascularization. Ann Ophthalmol 1988 20 426-427 430
30. Baughman R P., Lower E E., Bradley D A., Raymond L A., Kaufman A. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest 2005 128 1062-47
31. Rothova A, Suttorp-van Schulten M S., Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 1996 80 332-336
32. Mayers M. Ocular sarcoidosis. Int Ophthalmol Clin 1990 30 257-263
33. Zajicek J P., Scolding N J., Foster O et al. Central nervous system sarcoidosisdiagnosis and management. QJM 1999 92 103-117
34. Lower E E., Broderick J P., Brott T G., Baughman R P. Diagnosis and management of neurological sarcoidosis. Arch Intern Med 1997 157 1864-1868
35. Baughman R P., Bradley D A., Lower E E. Infliximab in chronic ocular inflammation. Int J Clin Pharmacol Ther 2005 43 7-11
36. Salama B, Gicquel J J., Lenoble P, Dighiero P L. Optic neuropathy in refractory neurosarcoidosis treated with TNF-alpha antagonist. Can J Ophthalmol 2006 41 766-768
37. Mumoli N, Niccoli G, Scazzeri F, Picchietti S, Greco A, Cei M. Infliximab-induced retrobulbar optic neuritis. QJM 2007 100 531
38. Simsek I, Erdem H, Pay S, Sobaci G, Dinc A. Optic neuritis occurring with anti-tumour necrosis factor alpha therapy. Ann Rheum Dis 2007 66 1255-1258
39. Peterson E A., Hymas D C., Pratt D V., Mortenson S W., Anderson R L., Mamalis N. Sarcoidosis with orbital tumor outside the lacrimal gland: initial manifestation in 2 elderly white women. Arch Ophthalmol 1998 116 804-806
40. Linberg J V., McCormick S A. Primary acquired nasolacrimal duct obstruction: a clinicopathologic report and biopsy technique. Ophthalmology 1986 93 1055-1063
41. Anderson N G., Wojno T H., Grossniklaus H E. Clinicopathologic findings from lacrimal sac biopsy specimens obtained during dacryocystorhinostomy. Ophthal Plast Reconstr Surg 2003 19 173-176
42. Merkonidis C, Brewis C, Yung M, Nussbaumer M. Is routine biopsy of the lacrimal sac wall indicated at dacryocystorhinostomy? A prospective study and literature review. Br J Ophthalmol 2005 89 1589-1591
43. Baughman R P., Lower E E., Tami T. Upper airway, IV: Sarcoidosis of the upper respiratory tract (SURT). Thorax 2010 65 181-186
44. Yanardag H, Pamuk O N. Lacrimal gland involvement in sarcoidosis. The clinical features of 9 patients. Swiss Med Wkly 2003 133 388-391
45. DeRemee R A. Sarcoidosis and Wegeners granulomatosis: a comparative analysis. Sarcoidosis 1994 11 7-18
46. Wertheim M S., Mathers W D., Suhler E B., Wilson D J., Rosenbaum J T. Histopathological features of conjunctival sarcoid nodules using noninvasive in vivo confocal microscopy. Arch Ophthalmol 2005 123 274-276
47. Samson C M., Waheed N, Baltatzis S, Foster C S. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology 2001 108 1134-1139
48. Baughman R P., Lower E E. Sarcoidosis In: Fauci AS, Braunwald E, Kasper DL, et al Harrison's Principles of Internal Medicine. New York McGraw-Hill 2008 2135-2142
49. Ohara K, Okubo A, Kamata K, Sasaki H, Kobayashi J, Kitamura S. Transbronchial lung biopsy in the diagnosis of suspected ocular sarcoidosis. Arch Ophthalmol 1993 111 642-644
50. Clement D S., Postma G, Rothova A, Grutters J C., Prokop M, de Jong P A. Intraocular sarcoidosis: association of clinical characteristics of uveitis with positive chest high-resolution computed tomography findings. Br J Ophthalmol 2010 94 219-222
51. Baughman R P., Drent M. Role of bronchoalveolar lavage in interstitial lung disease. Clin Chest Med 2001 22 331-341
52. Bienfait M F., Hoogsteden H C., Baarsma G S., Adriaansen H J., Verheijen-Breemhaar L. Diagnostic value of bronchoalveolar lavage in ocular sarcoidosis. Acta Ophthalmol (Copenh) 1987 65 745-748
53. Jouveshomme S, Fardeau C, Finet J F. et al. Alveolar lymphocytosis in patients with chronic uveitis: relationship to sarcoidosis. Lung 2001 179 305-317
54. Controlled evaluation of loteprendnol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Loteprednol etabonate US uveitis study. Am J Ophthalmol 1999 127 537-544
55. Hirano Y, Ito T, Nozaki M et al. Intraocular pressure elevation following triamcinolone acetonide administration as related to administration routes. Jpn J Ophthalmol 2009 53 519-522
56. Eljarrat-Binstock E, Peer J, Domb A J. New techniques for drug delivery to the posterior eye segment. Pharm Res 2010 27 530-543
57. Pavesio C, Zierhut M, Bairi K, Comstock T L., Usner D W., Fluocinolone Acetonide Study Group. Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis. Ophthalmology 2010 117 567-575 e1
58. Kempen J H., Altaweel M M., Holbrook J T., Jabs D A., Sugar E A., Multicenter Uveitis Steroid Treatment Trial Research Group. The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics. Am J Ophthalmol 2010 149 550-561 e10
59. Galor A, Jabs D A., Leder H A. et al. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology 2008 115 1826-1832
60. Baughman R P., Costabel U, du Bois R M. Treatment of sarcoidosis. Clin Chest Med 2008 29 533-548 ix-x
61. Dev S, McCallum R M., Jaffe G J. Methotrexate treatment for sarcoid-associated panuveitis. Ophthalmology 1999 106 111-118
62. Veien N K. Cutaneous sarcoidosis: prognosis and treatment. Clin Dermatol 1986 4 75-87
63. Baughman R P., Lower E E., Bradley D A. et al. Use of cytotoxic therapy for chronic ophthalmic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999 16 S17
64. Shetty A K., Zganjar B E., Ellis G S. Jr, Ludwig I H., Gedalia A. Low-dose methotrexate in the treatment of severe juvenile rheumatoid arthritis and sarcoid iritis. J Pediatr Ophthalmol Strabismus 1999 36 125-128
65. Maust H A., Foroozan R, Sergott R C., Niazi S, Weibel S, Savino P J. Use of methotrexate in sarcoid-associated optic neuropathy. Ophthalmology 2003 110 559-563
66. Lower E E., Baughman R P. The use of low dose methotrexate in refractory sarcoidosis. Am J Med Sci 1990 299 153-157
67. Taylor S R., Habot-Wilner Z, Pacheco P, Lightman S L. Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular edema. Ophthalmology 2009 116 797-801
68. Baughman R P., Lower E E. Alternatives to corticosteroids in the treatment of sarcoidosis. Sarcoidosis 1997 14 121-130
69. Mller-Quernheim J, Kienast K, Held M, Pfeifer S, Costabel U. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J 1999 14 1117-1122
70. Pasadhika S, Kempen J H., Newcomb C W. et al. Azathioprine for ocular inflammatory diseases. Am J Ophthalmol 2009 148 500-509 e2
71. Deuter C M., Doycheva D, Stuebiger N, Zierhut M. Mycophenolate sodium for immunosuppressive treatment in uveitis. Ocul Immunol Inflamm 2009 17 415-419
72. Bhat P, Cervantes-Castaeda R A., Doctor P P., Anzaar F, Foster C S. Mycophenolate mofetil therapy for sarcoidosis-associated uveitis. Ocul Immunol Inflamm 2009 17 185-190
73. Baughman R P., Lower E E. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004 21 43-48
74. Reiff A, Takei S, Sadeghi S et al. Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 2001 44 1411-1415
75. Foster C S., Tufail F, Waheed N K. et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 2003 121 437-440
76. Smith J A., Thompson D J., Whitcup S M. et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 2005 53 18-23
77. Schmeling H, Horneff G. Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology (Oxford) 2005 44 1008-1011
78. Hashkes P J., Shajrawi I. Sarcoid-related uveitis occurring during etanercept therapy. Clin Exp Rheumatol 2003 21 645-646
79. Galor A, Perez V L., Hammel J P., Lowder C Y. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 2006 113 2317-2323
80. Tynjl P, Lindahl P, Honkanen V, Lahdenne P, Kotaniemi K. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 2007 66 548-550
81. Diaz-Llopis M, Garca-Delpech S, Salom D et al. Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther 2008 24 351-361
82. Tynjl P, Kotaniemi K, Lindahl P et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford) 2008 47 339-344
83. Sandborn W J., Hanauer S, Loftus E V. Jr et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohns disease. Am J Gastroenterol 2004 99 1984-1989
84. Lim L L., Fraunfelder F W., Rosenbaum J T. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 2007 56 3248-3252
85. Daen C I., Monnier A, Claudepierre P et al, Club Rhumatismes et Inflammation (CRI). Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford) 2009 48 883-886
86. Ramos-Casals M, Brito-Zern P, Soto M J., Cuadrado M J., Khamashta M A. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 2008 22 847-861
87. Sweiss N J., Baughman R P. Tumor necrosis factor inhibition in the treatment of refractory sarcoidosis: slaying the dragon? J Rheumatol 2007 34 2129-2131
88. Crick P P., Hoyle C, Smellie H. The eye in sarcoidosis. Br J Dis Chest 1961 45 461-481
89. James D G., Anderson R, Langley D, Ainslie D. Ocular sarcoidosis. Br J Ophthalmol 1964 48 461-470
90. Karma A, Huhti E, Poukkula A. Course and outcome of ocular sarcoidosis. Am J Ophthalmol 1988 106 467-472